Press Releases 2023 2022 2021 2020 2019 all August 3, 2020 Dyne Therapeutics Appoints Susanna High as Chief Operating Officer July 20, 2020 Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board June 11, 2020 Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property May 19, 2020 Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board May 12, 2020 Dyne Therapeutics Demonstrates FORCE TM Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy May 11, 2020 Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory April 23, 2020 Dyne Therapeutics Appoints David Lubner to Board of Directors March 31, 2020 Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD February 6, 2020 Dyne Therapeutics Expands Leadership Team with Key Hires January 13, 2020 Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy October 1, 2019 Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer September 23, 2019 Dyne Therapeutics Announces Support for ReSolve Natural History Study of Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) August 19, 2019 Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein June 28, 2019 Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors June 17, 2019 Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1) June 13, 2019 Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12) April 3, 2019 Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Displaying 61 - 77 of 77
